- Home
- Automated
- List of product information
- SELEGOS TABLET 5 MG [SIN08681P]
SELEGOS TABLET 5 MG [SIN08681P]
Active ingredients: SELEGOS TABLET 5 MG
Last updated 26 October 2025
On this page
Product Info
SELEGOS TABLET 5 MG
[SIN08681P]
Product information
Active Ingredient and Strength | SELEGILINE HCL - 5 MG |
Dosage Form | TABLET |
Manufacturer and Country | MEDOCHEMIE LTD - CYPRUS |
Registration Number | SIN08681P |
Licence Holder | MEDOCHEMIE SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | N04BD01 |
4.1. Therapeutic indications
SELEGOS is indicated for the treatment of Parkinson’s disease or symptomatic parkinsonism.
SELEGOS may be used alone in early Parkinson’s disease to delay the need for levodopa (with or without decarboxylase inhibitor). SELEGOS may also be used as an adjunct to levodopa (with or without decarboxylase inhibitor).
4.2. Posology and method of administration
SELEGOS 10mg (2 tablets) daily either alone or as an adjunct to levodopa or levodopa/peripheral decarboxylase inhibitor.
SELEGOS may be administered either as a single dose in the morning or in two divided doses of 5mg taken at breakfast and lunch.
When SELEGOS is added to a levodopa regimen it is possible to reduce the levodopa dosage by an average of 30 percent.
4.3. Contraindications
None.